Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dulce Brito

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Journal of Cardiovascular Development and Disease|October 28, 2025
Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA CohortEva H van der Geest, Nina Ajmone Marsan, Dorien Laenens, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|December 2, 2020
Telehealth Opportunities in the COVID-19 Pandemic Early Days: What Happened, Did Not Happen, Should Have Happened, and Must Happen in the Near Future?Paula Amorim, Dulce Brito, Miguel Castelo-Branco, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|September 2, 2024
Right Ventricular to Pulmonary Artery Coupling and Prognosis in Transthyretin Cardiac AmyloidosisMaria Chiara Meucci, Dorien Laenens, Rosa Lillo, et al.
Biomedicines|October 29, 2025
Fabry Disease Screening in Patients with Idiopathic HCM or LVH: Data from the Multicentric Nationwide F-CHECK StudyRaquel Machado, Inês Fortuna, Sílvia Sousa, et al.
ESC Heart Failure|February 19, 2026
Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort studyDorien Laenens, Philippe Debonnaire, Maarten A J De Smet, et al.
Global Heart|October 30, 2023
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)Dulce Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 9, 2022
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registryLuis R Lopes, Maria-Angela Losi, Nabeel Sheikh, et al.
Intensive Care Medicine|January 27, 2025
Role of major cardiovascular surgery-induced metabolic reprogramming in acute kidney injury in critical careTiago R Velho, Francisco Pinto, Ricardo Ferreira, et al.
ESC Heart Failure|June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
JAMA Cardiology|September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical TrialJean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Journal of Cardiovascular Development and Disease|October 28, 2025
Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA CohortEva H van der Geest, Nina Ajmone Marsan, Dorien Laenens, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|December 2, 2020
Telehealth Opportunities in the COVID-19 Pandemic Early Days: What Happened, Did Not Happen, Should Have Happened, and Must Happen in the Near Future?Paula Amorim, Dulce Brito, Miguel Castelo-Branco, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|September 2, 2024
Right Ventricular to Pulmonary Artery Coupling and Prognosis in Transthyretin Cardiac AmyloidosisMaria Chiara Meucci, Dorien Laenens, Rosa Lillo, et al.
Biomedicines|October 29, 2025
Fabry Disease Screening in Patients with Idiopathic HCM or LVH: Data from the Multicentric Nationwide F-CHECK StudyRaquel Machado, Inês Fortuna, Sílvia Sousa, et al.
ESC Heart Failure|February 19, 2026
Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort studyDorien Laenens, Philippe Debonnaire, Maarten A J De Smet, et al.
Global Heart|October 30, 2023
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)Dulce Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 9, 2022
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registryLuis R Lopes, Maria-Angela Losi, Nabeel Sheikh, et al.
Intensive Care Medicine|January 27, 2025
Role of major cardiovascular surgery-induced metabolic reprogramming in acute kidney injury in critical careTiago R Velho, Francisco Pinto, Ricardo Ferreira, et al.
ESC Heart Failure|June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
JAMA Cardiology|September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical TrialJean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
Pageof 13